Utilidad de los marcadores tumorales en pacientes femeninas con cáncer de mama atendidas en el Hospital del día SULAB durante el año 2024

Yessenia del Rocío Carpio Quito; Karina Maricela  Merchán Villafuerte

doi:10.70577/asce.v4i4.460

Authors

Yessenia del Rocío Carpio Quito Universidad Estatal del Sur de Manabí https://orcid.org/0009-0007-1584-8580
Karina Maricela Merchán Villafuerte Universidad Estatal del Sur de Manabí https://orcid.org/0000-0001-6128-4893

DOI:

https://doi.org/10.70577/asce.v4i4.460

Keywords:

Breast cancer; CEA; CA 15-3; HER2; Tumor markers

Abstract

Breast cancer was the leading malignancy in women and a significant cause of mortality. Its management required diagnostic tools that assessed spread, therapeutic response, and risk of recurrence. In this context, the markers CA 15-3, CEA, and HER2 provided complementary support to clinical follow-up. The purpose was to analyze the clinical effectiveness of these indicators in women with breast cancer treated at SULAB Day Hospital in 2024. A retrospective, cross-sectional, and analytical analysis was conducted with 200 women. Sociodemographic and clinical data were collected on the analytes CA 15-3 and CEA in serum and HER2 in tissue. The markers were correlated with stage, therapeutic response, and recurrence. The analysis was performed in IBM SPSS v27 with Chi-square and association measures (Φ and Cramer's V), with significance set at p < 0.05. CA 15-3 and CEA decreased after treatment (p < 0.001). HER2 showed a moderate-to-strong association with response and recurrence (V = 0.447). 2+/3+ overexpression was associated with a lower clinical response, while normal CA 15-3 values were related to a favorable outcome. The combined evaluation of CA 15-3, CEA, and HER2 provided complementary value for therapeutic monitoring and early detection of recurrence. Its interpretation, along with clinical and imaging data, strengthened timely therapeutic decisions and more precise follow-up in the institutional setting studied.

Downloads

Download data is not yet available.

References

Abarca, J., & Jiménez, P. (2020, mayo 3). Eficacia del CA 15.3, en el seguimiento del tratamiento y evolución, en pacientes de 35-75 años con cáncer de mama en el HETMC, junio 2018—Junio 2019. [Tesis de titulación, Universidad Católica de Santiago de Guayaquil]. Repositorio de la Universidad Católica de Santiago de Guayaquil. http://repositorio.ucsg.edu.ec/handle/3317/14877

Arenillas, M., & Ortiz, J. (2022). CA 15-3 Tumor Marker in Invasive Breast Carcinoma of non-special type (ductal) . Anatomía Digital, 5(3.3), 58-5. https://doi.org/10.33262/anatomiadigital.v5i3.3.2331 DOI: https://doi.org/10.33262/anatomiadigital.v5i3.3.2331

Balladares, A., Cambal, S., & Santana, L. (2023, noviembre 17). Marcadores tumorales séricos, como ayuda diagnóstica en el cáncer de mama. http://dspace.unach.edu.ec/handle/51000/11872

College of American Pathologists. (2023). HER2 Breast Cancer Testing Guideline Update Algorithms. https://documents.cap.org/documents/her2_breast_update_algorithms_2023.pdf

GLOBOCAN. (2022). GLOBOCAN 2022. https://gco.iarc.who.int/media/globocan/factsheets/populations/218-ecuador-fact-sheet.pdf

Hasan, D. (2022). Diagnostic impact of CEA and CA 15-3 on chemotherapy monitoring of breast cancer patients. Journal of Circulating Biomarkers, 11, 57-63. https://doi.org/10.33393/jcb.2022.2446 DOI: https://doi.org/10.33393/jcb.2022.2446

Instituto Nacional de Estadística y Censos. (2017, octubre 18). El cáncer de mama en Ecuador. https://www.ecuadorencifras.gob.ec/el-cancer-de-mama-en-ecuador

Kang, S., & Kim, S.-B. (2024). HER2-Low Breast Cancer: Now and in the Future. Cancer Research and Treatment, 56(3), 700-720. https://doi.org/10.4143/crt.2023.1138 DOI: https://doi.org/10.4143/crt.2023.1138

Loibl, S., André, F., Bachelot, T., Barrios, C. H., Bergh, J., Burstein, H. J., Cardoso, M. J., Carey, L. A., Dawood, S., Del Mastro, L., Denkert, C., Fallenberg, E. M., Francis, P. A., Gamal-Eldin, H., Gelmon, K., Geyer, C. E., Gnant, M., Guarneri, V., Gupta, S., … Harbeck, N. (2024). Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology : Official Journal of the European Society for Medical Oncology, 35(2), 159-182. https://doi.org/10.1016/j.annonc.2023.11.016 DOI: https://doi.org/10.1016/j.annonc.2023.11.016

Morales, D. (2018). Valor predictivo de los marcadores tumorales Ca 15-3 y Antígeno Carcinoembrionario CEA en el tratamiento y seguimiento de las pacientes con cáncer de mama atendidas en el Hospital de Especialidades Eugenio Espejo durante el año 2016 [Tesis de titulación, Universidad Central del Ecuador]. Repositorio Digital de la Universidad Central del Ecuador.. https://www.dspace.uce.edu.ec/entities/publication/bda232a5-d966-41f1-9c94-ba4f2278aa5f

Morales, D., & Echeverria, I. (2019). Biomarcadores mamarios en procesos metastásicos en mujeres ecuatorianas. https://www.dspace.uce.edu.ec/server/api/core/bitstreams/7e7a38e8-8f35-4466-bbdb-7e57443b22b0/content

Orbe, L., Pozo, J., & Bigoni, G. (2023). Sobreexpresión de HER-2 en pacientes con cáncer de mama en SOLCA-Cuenca. Revista de la Facultad de Ciencias Médicas de la Universidad de Cuenca, 41(2). https://doi.org/10.18537/RFCM.41.02.03 DOI: https://doi.org/10.18537/RFCM.41.02.03

Organización Mundial de la Salud. (2022). The Global Breast Cancer Initiative. https://www.who.int/initiatives/global-breast-cancer-initiative

Organización Mundial de la Salud. (2025, agosto 14). Breast cancer. Breast cancer. https://www.who.int/news-room/fact-sheets/detail/breast-cancer

Organización Panamericana de la Salud. (2020, febrero 1). Breast cancer. https://www.paho.org/en/topics/breast-cancer DOI: https://doi.org/10.26633/RPSP.2021.141

Organización Panamericana de la Salud. (2024). Cancer. https://www.paho.org/en/topics/cancer

Sinche, B., & Aucapiña, G. (2022). Valor predictivo de los marcadores tumorales CA 15.3 y CEA en el control y seguimiento de pacientes con cáncer de mama en el Hospital de Especialidades José Carrasco Arteaga en el período 2016-2019. [Tesis de titulación, Universidad de Cuenca]. Repositorio Digital de la Universidad de Cuenca. https://dspace.ucuenca.edu.ec/items/075e5200-1764-47da-ae67-7f9580df9d15

SOLCA. (2023a). Boletín Epidemiológico. Cáncer de Mama. 3, 1-15. DOI: https://doi.org/10.33610/23576189.2023.15

SOLCA. (2023b). Mortalidad por cáncer de mama en mujeres menores de 75 años Guayaquil. Período 2008-2022. http://www.estadisticas.med.ec/web/Publicaciones/1%20Boletin%20Epi%20Ca%20Mama%202023.pdf

Uygur, M. M., & Gümüş, M. (2021). The utility of serum tumor markers CEA and CA 15-3 for breast cancer prognosis and their association with clinicopathological parameters. Cancer Treatment and Research Communications, 28, 100402. https://doi.org/10.1016/j.ctarc.2021.100402 DOI: https://doi.org/10.1016/j.ctarc.2021.100402

Wolf, A., Somerfield, M., Dowsett, M., Hammond, E., & Hayes, D. (2023). Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology–College of American Pathologists Guideline Update. Arch Pathol Lab Med, 147(9), 993-1000. https://doi.org/10.1200/JCO.22.02864 DOI: https://doi.org/10.1200/JCO.22.02864